Adage Capital Partners’s Avalo Therapeutics AVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$24.5M Sell
1,600,000
-129,000
-7% -$2.37M 0.03% 433
2026
Q2
$32M Buy
1,729,000
+875,000
+102% +$13.8M 0.04% 375
2026
Q1
$12.8M Buy
854,000
+304,000
+55% +$4.75M 0.02% 626
2025
Q4
$10M Buy
550,000
+291,231
+113% +$4.92M 0.02% 667
2025
Q3
$3.29M Buy
+258,769
New +$2.23M 0.01% 773

Other funds holding AVTX

Adage Capital Partners's AVTX Position: Q3 2026 in Review

Adage Capital Partners reduced its Avalo Therapeutics (AVTX) stake by 7.5% in Q3 2026, selling an estimated $2.37M and leaving 1,600,000 shares worth $24.5M. The position accounts for 0.03% of the portfolio, ranked #433.

Adage Capital Partners first reported a position in AVTX in Q3 2025 and has held it in 5 quarters since. The position peaked at $32M in Q2 2026. 148 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.

  • Adage Capital Partners held 1,600,000 shares of Avalo Therapeutics worth $24.5M as of Q3 2026.
  • Adage Capital Partners sold 129,000 Avalo Therapeutics shares in Q3 2026, an estimated $2.37M.
  • Avalo Therapeutics made up 0.03% of Adage Capital Partners's portfolio in Q3 2026, its #433 holding.
  • Adage Capital Partners first reported a position in Avalo Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Adage Capital Partners's Avalo Therapeutics position peaked at $32M in Q2 2026.
  • 148 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.

Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.